Amikacin Therapy: Indications, Dosing, Duration, and Monitoring
Primary Indications
Amikacin is a second-line injectable aminoglycoside primarily indicated for drug-resistant tuberculosis and non-tuberculous mycobacterial (NTM) pulmonary disease when organisms demonstrate susceptibility. 1, 2 It is not routinely recommended for drug-susceptible M. kansasii disease 3. Amikacin retains activity against most aerobic Gram-negative bacteria, including multidrug-resistant Enterobacterales and Pseudomonas, though its use is limited by significant toxicity concerns 4.
Dosing Regimens
For Tuberculosis and NTM Disease
Adults:
- 15 mg/kg once daily (maximum 1.0 g/day) intramuscularly or intravenously, given 5-7 days/week initially 1, 2
- Alternative: 7.5 mg/kg twice daily 5
- Intermittent dosing: 15-25 mg/kg three times per week after the first 2-4 months or after culture conversion 5, 1, 2
- Age >59 years: Reduce to 10 mg/kg/day (750 mg maximum) 1, 2
Children:
Obesity adjustment: Use ideal body weight plus 40% of excess weight due to decreased distribution in adipose tissue 5
- Male IBW (kg) = 50 + (2.3 × height in cm above 152.4)/2.54
- Female IBW (kg) = 45.5 + (2.3 × height in cm above 152.4)/2.54
For Severe Gram-Negative Infections
Recent evidence suggests higher doses may be needed:
- 25-30 mg/kg for critically ill patients 6, 7
- A fixed dose of 2500 mg may optimize target attainment in emergency surgery patients 7
Renal Impairment
Critical adjustment required: Maintain dose at 12-15 mg/kg but reduce frequency to 2-3 times per week 1, 2, 1. Smaller doses reduce efficacy due to concentration-dependent bactericidal effect. Give after dialysis to facilitate directly observed therapy and avoid premature drug removal 1, 2.
Nebulized Amikacin (for NTM-PD)
- 500 mg twice daily via nebulizer with filter attachment 5
- Use 250 mg/mL injection diluted to 4 mL with 0.9% sodium chloride
- Administer bronchodilator (e.g., salbutamol) prior to reduce bronchospasm risk 5
- Dose reduction to 250-500 mg once or twice daily may be considered for intolerance 5
Treatment Duration
Standard duration: 7-10 days for typical infections 8. For NTM disease, continue daily or 5-7 days/week initially, then reduce to 2-3 times per week after 2-4 months or culture conversion, depending on regimen efficacy 1, 2.
If treatment extends beyond 10 days, mandatory re-evaluation is required with continued monitoring of serum levels, renal function, and auditory/vestibular function 8. Treatment should be limited to short-term whenever feasible due to cumulative toxicity risk.
Therapeutic Drug Monitoring (TDM)
Target Concentrations
Intravenous/Intramuscular:
- Trough: <5 mg/L (mandatory to avoid toxicity) 5, 8
- Peak (daily dosing): 25-35 mg/L 5 or 35-45 μg/mL 3
- Peak (intermittent dosing): 65-80 mg/L 5, 3
Nebulized:
- Trough: <5 mg/L 5
Sampling Timing
Peak:
- Take levels at 90-120 minutes AND 6 hours after infusion ends, plot on semilogarithmic paper, and extrapolate back to time=0 5
- Alternative: 60 minutes post-infusion (may underestimate true peak) 5
- FDA label states 30-90 minutes post-injection 8
Trough: Immediately before next dose 5
Monitoring Frequency
Intravenous:
- Peak: First week, repeat if poor response 5
- Trough: Weekly for 4 weeks, then reduce to fortnightly when stable 5
Nebulized:
- Trough: 1 week after starting, then as needed 5
Dose Adjustments Based on Levels
Safety Monitoring
Baseline Assessment (Mandatory)
During Therapy
Renal Function:
- Intravenous: Twice weekly during month 1, weekly during month 2, then fortnightly 5
- Nebulized: Monthly (increase frequency if impairment develops) 5
- Monthly assessment with questioning about auditory/vestibular symptoms 1, 2
Auditory/Vestibular:
- Repeat audiogram and vestibular testing if symptoms develop (tinnitus, vertigo, balance loss) 5, 1, 2
- Ototoxicity definition: 20 dB loss at any one frequency OR 10 dB loss at two adjacent frequencies 5
- Action if ototoxicity detected: Discontinue or reduce frequency; hearing loss is likely permanent 5
Major Adverse Effects
Nephrotoxicity
- More common than streptomycin 1, 2, 1
- Occurs in 8.7% overall; 3.4% in patients without risk factors 1, 2
- Risk factors: Pre-existing renal impairment, higher cumulative doses, concomitant nephrotoxic agents (especially vancomycin, capreomycin, cephalosporins, ciclosporin) 1, 2, 4
Ototoxicity
- High-frequency hearing loss in 1.5-24% of patients (higher with longer treatment/higher doses) 1, 2, 1
- Auditory damage more common than vestibular (opposite of streptomycin) 1, 2
- Increased risk with loop diuretics 5, 1
- Irreversible vestibulocochlear nerve damage 5
Other Serious Effects
- Hypocalcemia, hypomagnesemia, hypokalaemia 5
- Neuromuscular blockade and respiratory paralysis (dose-related, more common in neuromuscular disease) 5
Contraindications and Cautions
Absolute Contraindications:
- Pregnancy (risk of fetal nephrotoxicity and congenital hearing loss) 1, 2, 1, 5, 1
- Hypersensitivity to aminoglycosides 5
- Myasthenia gravis (impairs neuromuscular transmission) 5
Use with Extreme Caution:
- Elderly patients (higher nephrotoxicity and ototoxicity risk) 5
- Pre-existing renal impairment 1, 2, 1
- Severe hepatic disease (predisposition to hepato-renal syndrome) 1
Critical Clinical Pitfalls
Do not use fixed dosing without weight-based calculation 8 - except possibly 2500 mg in emergency surgery 7
Never reduce the milligram dose in renal impairment - only extend the interval to maintain concentration-dependent killing 1, 2, 1
Do not co-prescribe with other aminoglycosides (streptomycin, kanamycin, capreomycin) - no clinical benefit 5
Nebulized amikacin must not be mixed with other nebulized drugs (salbutamol, dornase alfa, other antibiotics) - only mix with 0.9% sodium chloride 5
Peak concentrations above 35 mcg/mL and trough above 10 mcg/mL should be avoided per FDA labeling 8, though higher peaks (35-45 mcg/mL) are recommended in some NTM guidelines 3
TDM is not optional - serum concentrations should be measured whenever possible to ensure adequate but not excessive levels 8
Clinical response should occur within 3-5 days - if not, stop therapy and recheck susceptibility 8